· Research and development costs amounted to SEK 3.2 (3.8) m
· The loss after tax was SEK -4.2 (-5.0) m
· Earnings per share were SEK -0.02 (-0.06)
· The company had no net sales for the period
· The controlled phase II clinical study of ChronVac-C® in combination with standard-of-care is ongoing.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail:  

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®....